Fulgent Genetics, Inc.
General ticker "FLGT" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $609.1M (TTM average)
Fulgent Genetics, Inc. follows the US Stock Market performance with the rate: 51.1%.
Estimated limits based on current volatility of 2.0%: low 28.02$, high 29.16$
Factors to consider:
- Total employees count: 1313 (+10.9%) as of 2024
- US accounted for 91.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Cybersecurity threats, Strategic risks and growth management, Integration of acquired businesses, Labor/talent shortage/retention, Operational and conduct risks
- Current price 49.5% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [11.40$, 21.46$]
- 2025-12-31 to 2026-12-31 estimated range: [9.72$, 18.78$]
Financial Metrics affecting the FLGT estimates:
- Positive: with PPE of 37.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0.03 <= 0.74
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: -3.57 < Return on assets ratio (scaled to [-100,100]) of -3.47
- Positive: -14.19 < Investing cash flow per share per price, % of -10.41
Short-term FLGT quotes
Long-term FLGT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $618.97MM | $289.21MM | $283.47MM |
| Operating Expenses | $440.44MM | $484.74MM | $357.39MM |
| Operating Income | $178.53MM | $-195.53MM | $-73.92MM |
| Non-Operating Income | $5.50MM | $21.44MM | $21.96MM |
| Interest Expense | $1.01MM | $0.49MM | $0.17MM |
| R&D Expense | $28.91MM | $41.44MM | $48.82MM |
| Income(Loss) | $184.03MM | $-174.09MM | $-51.96MM |
| Taxes | $42.10MM | $1.15MM | $-8.14MM |
| Profit(Loss)* | $143.40MM | $-167.82MM | $-42.71MM |
| Stockholders Equity | $1,266.68MM | $1,136.10MM | $1,133.23MM |
| Inventory | $4.28MM | $0.00MM | $8.38MM |
| Assets | $1,386.05MM | $1,235.33MM | $1,219.96MM |
| Operating Cash Flow | $253.52MM | $27.00MM | $21.06MM |
| Capital expenditure | $18.77MM | $22.21MM | $40.31MM |
| Investing Cash Flow | $-261.31MM | $38.90MM | $-58.35MM |
| Financing Cash Flow | $-77.14MM | $-47.78MM | $-4.85MM |
| Earnings Per Share** | $4.76 | $-5.63 | $-1.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.